Overview and recent advances in the treatment of neuroblastoma

References

• Ries L, Smith M, Gurney J, et al. Cancer incidence and survival among children and adolescents: united States SEER Program 1975–1995, National Cancer Institute, SEER Program. Bethesda (MD): NIH Pub; 1999. p. 99–4649.
   Google Scholar
• Stiller CA, Parkin DM. International variations in the incidence of neuroblastoma. Int J Cancer. 1992;52:538–543.
   PubMed Web of Science ®Google Scholar
• Heck JE, Ritz B, Hung RJ, et al. The epidemiology of neuroblastoma: a review. Paediatr Perinat Epidemiol. 2009;23:125–143.
   PubMed Web of Science ®Google Scholar
• Irwin MS, Park JR. Neuroblastoma: paradigm for precision medicine. Pediatr Clin NA. 2015;62:225–256.
   PubMed Web of Science ®Google Scholar
• Henderson TO, Bhatia S, Pinto N, et al. Racial and ethnic disparities in risk and survival in children with neuroblastoma: a Children’s Oncology Group study. J Clin Oncol. 2011;29:76–82.
   PubMed Web of Science ®Google Scholar
• Yamamoto K, Ohta S, Ito E, et al. Marginal decrease in mortality and marked increase in incidence as a result of neuroblastoma screening at 6 months of age: cohort study in seven prefectures in Japan. J Clin Oncol. 2002;20:1209–1214.
   PubMed Web of Science ®Google Scholar
• Hiyama E, Iehara T, Sugimoto T, et al. Effectiveness of screening for neuroblastoma at 6 months of age: a retrospective population-based cohort study. Lancet. 2008;371:1173–1180.
   PubMed Web of Science ®Google Scholar
• Schilling FH, Spix C, Berthold F, et al. Neuroblastoma screening at one year of age. N Engl J Med. 2002;346:1047–1053.
   PubMed Web of Science ®Google Scholar
• Woods WG, Gao RN, Shuster JJ, et al. Screening of infants and mortality due to neuroblastoma. N Engl J Med. 2002;346:1041–1046.
   PubMed Web of Science ®Google Scholar
• Maris JM, Woods WG. Screening for neuroblastoma: a resurrected idea? Lancet. 2008;371:1142–1143.
   PubMed Web of Science ®Google Scholar
• Cook MN, Olshan AF, Guess HA, et al. Maternal medication use and neuroblastoma in offspring. Am J Epidemiol. 2004;159:721–731.
   PubMed Web of Science ®Google Scholar
• Menegaux F, Olshan AF, Nelgia JP, et al. Day care, childhood infections, and risk of neuroblastoma. Am J Epidmiol. 2004;159:843–851.
   PubMed Web of Science ®Google Scholar
• McDermott S, Salzberg DC, Anderson AP, et al. Systematic review of chromium and nickel exposure during pregnancy and impact on child outcomes. J Toxicol Environ Health A. 2015;78:1348–1368.
   PubMed Web of Science ®Google Scholar
• Shojaei-Brosseau T, Chompret A, Abel A, et al. Genetic epidemiology of neuroblastoma: a study of 426 cases at the Institut Gustave-Roussy in France. Pediatr Blood Cancer. 2004;42:99–105.
   PubMed Web of Science ®Google Scholar
• Trochet D, Bourdeaut F, Janoueix-Lerosey I, et al. Germline mutations of the paired-like homeobox 2B (PHOX2B) gene in neuroblastoma. Am J Hum Genet. 2004;74:761–764.
   PubMed Web of Science ®Google Scholar
• Rohrer T, Trachsel D, Engelcke G, et al. Congenital central hypoventilation syndrome associated with Hirschsprung’s disease and neuroblastoma: case of multiple neurocristopathies. Pediatr Pulmonol. 2002;33:71–76.
   PubMed Web of Science ®Google Scholar
• Mosse YP, Laudenslager M, Khazi D, et al. Germline PHOX2B mutation in hereditary neuroblastoma. Am J Hum Genet. 2004;75:727–730.
   PubMed Web of Science ®Google Scholar
• Clausen N, Andersson P, Tommerup N. Familial occurrence of neuroblastoma, von Recklinghausen’s neurofibromatosis, Hirschsprung’s agangliosis and jaw-winking syndrome. Acta Paediatr Scand. 1989;78:736–741.
   PubMed Web of Science ®Google Scholar
• Mosse YP, Laudenslager M, Longo L, et al. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature. 2008;455:930–935.
   PubMed Web of Science ®Google Scholar
• Janoueix-Lerosey I, Lequin D, Brugieres L, et al. Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature. 2008;455:967–970.
   PubMed Web of Science ®Google Scholar
• George RE, Sanda T, Hanna M, et al. Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature. 2008;455:975–978.
   PubMed Web of Science ®Google Scholar
• Chen Y, Takita J, Choi YL, et al. Oncogenic mutations of ALK kinase in neuroblastoma. Nature. 2008;455:971–974.
   PubMed Web of Science ®Google Scholar
• Schulte JH, Bachmann HS, Brockmeyer B, et al. High ALK receptor tyrosine kinase expression supersedes ALK mutation as a determining factor of an unfavorable phenotype in primary neuroblastoma. Clin Cancer Res. 2011;17:5082–5092.
   PubMed Web of Science ®Google Scholar
• Schleiermacher G, Javanmardi N, Bernard V, et al. Emergence of new ALK mutations at relapse of neuroblastoma. J Clin Oncol. 2014;32:2727–2734.
   PubMed Web of Science ®Google Scholar
• Bellini A, Bernard V, Leroy Q, et al. Deep sequencing reveals occurrence of subclonal ALK mutations in neuroblastoma at diagnosis. Clin Cancer Res. 2015;21:4913–4921.
   PubMed Web of Science ®Google Scholar
• Diskin SJ, Capasso M, Schnepp RW, et al. Common variation at 6q16 within HACE1 and LIN28B influences susceptibility to neuroblastoma. Nat Genet. 2012;44:1126–1130.
   PubMed Web of Science ®Google Scholar
• Capasso M, Devoto M, Hou C, et al. Common variations in BARD1 influence susceptibility to high-risk neuroblastoma. Nat Genet. 2009;41:718–723.
   PubMed Web of Science ®Google Scholar
• Wang K, Diskin SJ, Zhang H, et al. Integrative genomics identifies LMO1 as a neuroblastoma oncogene. Nature. 2011;469:216–220.
   PubMed Web of Science ®Google Scholar
• Whittle SB, Reyes S, Du M, et al. A polymorphism in the FGFR4 gene is associated with risk of neuroblastoma and altered receptor degradation. J Pediatr Hematol Oncol. 2016;38:131–138.
   PubMed Web of Science ®Google Scholar
• Maris JM, Mosse YP, Bradfield JP, et al. Chromosome 6p22 locus associated with clinically aggressive neuroblastoma. N Engl J Med. 2008;358:2585–2593.
   PubMed Web of Science ®Google Scholar
• Diskin SJ, Hou C, Glessner JT, et al. Copy number variation at 1q21.1 associated with neuroblastoma. Nature. 2009;459:987–991.
   PubMed Web of Science ®Google Scholar
• De Bernardi B, Balwierz W, Bejent J, et al. Epidural compression in neuroblastoma: diagnostic and therapeutic aspects. Cancer Lett. 2005;228:283–299.
   PubMed Web of Science ®Google Scholar
• Scheibel E, Rechnitzer C, Fahrenkrug J, et al. Vasoactive intestinal polypeptide (VIP) in children with neural crest tumours. Acta Paediatr Scand. 1982;71:721–725.
   PubMed Web of Science ®Google Scholar
• Matthay KK, Blaes F, Hero B, et al. Opsoclonus myoclonus syndrome in neuroblastoma: a report from a workshop on the dancing eyes syndrome at the advances in neuroblastoma meeting in Genoa, Italy, 2004. Cancer Lett. 2005;228:275–282.
   PubMed Web of Science ®Google Scholar
• Gorman MP. Update on diagnosis, treatment, and prognosis in opsoclonus-myoclonus-ataxia syndrome. Curr Opin Pediatr. 2010;22:745–750.
   PubMed Web of Science ®Google Scholar
• De Grandis E, Parodi S, Conte M, et al. Long-term follow-up of neuroblastoma-associated opsoclonus-myoclonus-ataxia syndrome. Neuropediatrics. 2009;40:103–111.
   PubMed Web of Science ®Google Scholar
• Catsman-Berrevoets CE, Aarsen FK, Van Hemsbergen ML, et al. Improvement of neurological status and quality of life in children with opsoclonus myoclonus syndrome at long-term follow-up. Pediatr Blood Cancer. 2009;53:1048–1053.
   PubMed Web of Science ®Google Scholar
• Sharp SE, Shulkin BL, Gelfand MJ, et al. 123I-MIBG scintigraphy and 18F-FDG PET in neuroblastoma. J Nucl Med. 2009;50:1237–1243.
   PubMed Web of Science ®Google Scholar
• Taggart DR, Han MM, Quach A, et al. Comparison of iodine-123 metaiodobenzylguanidine (MIBG) scan and [18F]fluorodeoxyglucose positron emission tomography to evaluate response after iodine-131 MIBG therapy for relapsed neuroblastoma. J Clin Oncol. 2009;27:5343–5349.
   PubMed Web of Science ®Google Scholar
• Bleeker G, Tytgat GAM, Adam JA, et al. 123I-MIBG scintigraphy and 18F-FDG-PET imaging for diagnosing neuroblastoma. Cochrane Database Syst Rev. 2015;9:CD009263. DOI:10.1002/14651858.CD009263.pub2
   Google Scholar
• Cheung NK, Heller G, Kushner BH, et al. Detection of neuroblastoma in bone marrow by immunocytology: is a single marrow aspirate adequate? Med Pediatr Oncol. 1999;32:84–87.
   PubMedGoogle Scholar
• Zage PE, Louis CU, Cohn SL. New aspects of neuroblastoma treatment: ASPHO 2011 symposium review. Pediatr Blood Cancer. 2012;58:1099–1105.
   PubMed Web of Science ®Google Scholar
• Shimada H, Ambros IM, Dehner LP, et al. Terminology and morphologic criteria of neuroblastic tumors: recommendations by the international neuroblastoma pathology committee. Cancer. 1999;86:349–363.
   PubMed Web of Science ®Google Scholar
• Peuchmaur M, d’Amore ES, Joshi VV, et al. Revision of the international neuroblastoma pathology classification: confirmation of favorable and unfavorable prognostic subsets in ganglioneuroblastoma, nodular. Cancer. 2003;98:2274–2281.
   PubMed Web of Science ®Google Scholar
• Navarro S, Amann G, Beiske K, et al. Prognostic value of international neuroblastoma pathology classification in localized resectable peripheral neuroblastic tumors: a histopathologic study of localized neuroblastoma European Study Group 94.01 Trial and Protocol. J Clin Oncol. 2006;24:695–699.
   PubMed Web of Science ®Google Scholar
• Brodeur GM, Seeger RC, Barrett A, et al. International criteria for diagnosis, staging, and response to treatment in patients with neuroblastoma. J Clin Oncol. 1988;6:1874–1881.
   PubMed Web of Science ®Google Scholar
• Brodeur GM, Pritchard J, Berthold F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol. 1993;11:1466–1477.
   PubMed Web of Science ®Google Scholar
• Cohn SL, Pearson AD, London WB, et al. The International Neuroblastoma Risk Group (INRG) classification system: an INRG task force report. J Clin Oncol. 2009;27:289–297.
   PubMed Web of Science ®Google Scholar
• Monclair T, Brodeur GM, Ambros PF, et al. The International Neuroblastoma Risk Group (INRG) staging system: an INRG task force report. J Clin Oncol. 2009;27:298–303.
   PubMed Web of Science ®Google Scholar
• Monclair T, Mosseri V, Cecchetto G, et al. Influence of image-defined risk factors on the outcome of patients with localised neuroblastoma. a report from the LNESG1 study of the European International Society of Paediatric Oncology Neuroblastoma group. Pediatr Blood Cancer. 2015;62:1536–1542.
   PubMed Web of Science ®Google Scholar
• Baker DL, Schmidt ML, Cohn SL, et al. Outcome after reduced chemotherapy for intermediate-risk neuroblastoma. New Engl J Med. 2010;363:1313–1323.
   PubMed Web of Science ®Google Scholar
• Strother DR, London WB, Schmidt ML, et al. Outcome after surgery alone or with restricted use of chemotherapy for patients with low risk neuroblastoma. J Clin Oncol. 2012;30:1842–1848.
   PubMed Web of Science ®Google Scholar
• Alvarado CS, London WB, Look AT, et al. Natural history and biology of stage A neuroblastoma: a Pediatric Oncology Group study. J Pediatr Hematol Oncol. 2000;22:197–205.
   PubMed Web of Science ®Google Scholar
• Perez CA, Matthay KK, Atkinson JB, et al. Biologic variables in the outcome of stages I and II neuroblastoma treated with surgery as primary therapy: a Childrens Cancer Group study. J Clin Oncol. 2000;18:18–26.
   PubMed Web of Science ®Google Scholar
• De Bernardi B, Mosseri V, Rubie H, et al. Treatment of localized resectable neuroblastoma. Results of the LNESG1 study by the SIOP Europe Neuroblastoma Group. Br J Cancer. 2008;99:1027–1033.
   PubMed Web of Science ®Google Scholar
• Nuchtern JG, London WB, Barnewolt CE, et al. A prospective study of expectant observation as primary therapy for neuroblastoma in young infants: a Children’s Oncology Group study. Ann Surgery. 2012;256:573–580.
   PubMed Web of Science ®Google Scholar
• Lavarino C, Cheung N-K, Garcia I, et al. Specific gene expression profiles and chromosomal abnormalities are associated with infant disseminated neuroblastoma. BMC Cancer. 2009;9:44.
   PubMed Web of Science ®Google Scholar
• Twist C, London WB, Naranjo A, et al. Maintaining Outstanding outcomes using response and biology based therapy for intermediate risk neuroblastoma: A report from the Children’s Oncology Group study ANBL0531. Presented at the Advances in Neuroblastoma Research Conference, Cologne, Germany, 2014 June.
   Google Scholar
• Kohler JA, Rubie H, Castel V, et al. Treatment of children over the age of one year with unresectable localised neuroblastoma without MYCN amplification; results of the SIOPEN study. Eur J Cancer. 2013;49:3671–3679.
   PubMed Web of Science ®Google Scholar
• Schleiermacher G, Michon J, Ribero A, et al. Segmental chromosomal alterations lead to a higher risk of relapse in infant with MYCN-nonamplified localised unresectable/disseminiated neuroblastoma (a SIOPEN collaborative study). Br J Cancer. 2011;105:1940–1948.
   PubMed Web of Science ®Google Scholar
• Berthold F, Boos J, Burdach S, et al. Myeloablative megatherapy with autologous stem cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial. Lancet Oncol. 2005;6:649–658.
   PubMed Web of Science ®Google Scholar
• Pearson AD, Pinkerton CR, Lewis IJ, et al. High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial. Lancet Oncol. 2008;9:247–256.
   PubMed Web of Science ®Google Scholar
• Matthay KK, Reynolds CP, Seeger RC, et al. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: A Children’s Oncology Group study. J Clin Oncol. 2009;27:1007–1013.
   PubMed Web of Science ®Google Scholar
• Kreissman SG, Seeger RC, Matthay KK, et al. Purged vs. non-purged peripheral blood stem cell transplantation for high risk neuroblastoma (COG A3973): a randomized phase III trial. Lancet Oncol. 2013;14:999–1008.
   PubMed Web of Science ®Google Scholar
• Yanik GA, Parisi MT, Shulkin BL, et al. Semiquantitative MIBG scoring as a prognostic indicator in patients with stage 4 neuroblastoma: a report from the Children’s Oncology Group. J Nucl Med. 2013;54:541–548.
   PubMed Web of Science ®Google Scholar
• Sorrentino S, Gigliotti AR, Sementa AR, et al. Neuroblastoma in the adult: the Italian experience with 21 patients. J Pediatr Hematol Oncol. 2014;36:e499–505.
   PubMed Web of Science ®Google Scholar
• Mosse YP, Deyell RJ, Berthold F, et al. Neuroblastoma in older children, adolescents and young adults: a report from the International Neuroblastoma Risk Group project. Pediatr Blood Cancer. 2014;61:627–635.
   PubMed Web of Science ®Google Scholar
• Park JR, Kreissman SG, London WB, et al. A Phase 3 Randomized Clinical Trial (RCT) of Tandem Myeloablative Autologous Stem Cell Transplant (ASCT) Using Peripheral Blood Stem Cell (PBSC) as Consolidation Therapy for High-Risk Neuroblastoma (HR-NB): A Children’s Oncology Group Study. Presented at the Advances in Neuroblastoma Research Conference, Cairns, Australia, 2016 June.
   Google Scholar
• Schrey D, Vaidya SJ, Levine D, et al. Additional Therapies to improve metastatic response to induction therapy in Children with High Risk Neuroblastoma. J Pediatr Hematol Oncol. 2015;37:e 150–153.
   Web of Science ®Google Scholar
• Simon T, Haberle B, Hero B, et al. Role of Surgery in the treatment of patients with stage 4 Neuroblastoma age 18 months or older at diagnosis. J Clin Oncol. 2013;31:752–758.
   PubMed Web of Science ®Google Scholar
• Du L, Liu L, Zhang C, et al. Role of Surgery in the treatment of patients with high risk neuroblastoma who have poor response to induction chemotherapy. J Pediatr Surg. 2014;49:528–533.
   PubMed Web of Science ®Google Scholar
• Castel V, Tovar JA, Costa E, et al. The Role of Surgery in Stage IV Neuroblastoma. J Pediatr Surg. 2002;37:1574–1578.
   PubMed Web of Science ®Google Scholar
• Mazloom A, Louis CU, Nuchtern J, et al. Radiation Therapy to the primary and post induction chemotherapy MIBG avid sites in high risk neuroblastoma. Int J Radiat Oncol Biol Phys. 2014;90:858–862.
   PubMed Web of Science ®Google Scholar
• Rombi B, MacDonald SM, Maurizio A, et al. Proton radiotherapy for childhood tumors: an overview of early clinical results. J Nucl Med Radiat Ther. 2013;4:4.
   Google Scholar
• Doyen J, Falk AT, Floquet V, et al. Proton beams in cancer treatments: clinical outcomes and dosimetric comparisons with photon therapy. Cancer Treat Rev. 2016;43:104–112.
   PubMed Web of Science ®Google Scholar
• Hattangadi JA, Rombi B, Yock TI, et al. Proton Radiotherapy for High-Risk Pediatric Neuroblastoma: early Outcomes and Dose Comparison. Int J Radiat Oncol Biol Phys. 2012;83:1015–1022.
   PubMed Web of Science ®Google Scholar
• Oshiro Y, Mizumoto M, Okkumura T, et al. Clinical Results of Proton Beam Therapy for Advanced Neuroblastoma. Radiat Oncol. 2013;8:142.
   PubMed Web of Science ®Google Scholar
• Yalcin B, Kremer LCM, van Dalen EC. High dose chemotherapy and autologous hematopoietic stem cell rescue for children with high risk neuroblastoma (Review). Cochrane Database Syst Rev. 2015;10:CD006301. doi: 10.1002/14651858.CD006301.pub4.
   Google Scholar
• Grupp SA, Cohn SL, Wall D, et al. Collection, storage, and infusion of stem cells in children with high-risk neuroblastoma: saving for a rainy day. Pedaitr Blood Cancer. 2006;46:719–722.
   PubMed Web of Science ®Google Scholar
• Fish JD, Grupp SA. Stem cell transplantation for neuroblastoma. Bone Marrow Transplant. 2008;41:159–165.
   PubMed Web of Science ®Google Scholar
• Ladenstein R, Poetschger U, Luksch R, et al. Busulfan-Melphalan as a myeloablative therapy (MAT) for high risk neuroblastoma: results from HR-NBL1/SIOPEN trial. J Clin Oncol. 2011;29:2.
   Web of Science ®Google Scholar
• Soni S, Pai V, Gross TG, et al. Busulfan and Melphalan as consolidation therapy with autologous peripheral blood stem cell transplantation following COG induction platform for high risk neuroblastoma; early results from a single institution. Pediatr Trans. 2014;18:217–220.
   PubMed Web of Science ®Google Scholar
• Seif AE, Naranjo A, Baker DL, et al. A pilot study of tandem high dose chemotherapy with stem cell rescue as consolidation for high risk neuroblastoma: Children’s Oncology Group study ANBL00P1. Bone Marrow Transplant. 2013;48:947–952.
   PubMed Web of Science ®Google Scholar
• Pasqualani C, Dufour C, Goma G, et al. Tandem high dose chemotherapy with thiotepa and busulfan-melphalan and autologous stem cell transplantation in very high risk neuroblastoma patients. Bone Marrow Transplant. 2016;51:227–231.
   PubMed Web of Science ®Google Scholar
• Kushner BH, Ostrovnaya I, Cheung IY, et al. Lack of survival advantage with autologous stem-cell transplantation in high-risk neuroblastoma consolidated by anti-GD2 immunotherapy and isotretinoin. Oncotarget. 2016;7:4155–4166.
   PubMed Web of Science ®Google Scholar
• Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. N Engl J Med. 1999;341:1165–1173.
   PubMed Web of Science ®Google Scholar
• Yu AL, Gilman AL, Ozkaynak F, et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med. 2010;363:1324–1334.
   PubMed Web of Science ®Google Scholar
• Cheung NK, Kushner BH, Cheung IY, et al. Anti-GD2 antibody treatment of minimal residual stage 4 neuroblastoma diagnosed at more than 1 year of age. J Clin Oncol. 1998;16:3053–3060.
   PubMed Web of Science ®Google Scholar
• Cheung NK, Cheung IY, Kushner BH, et al. Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony-stimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remission. J Clin Oncol. 2012;30:3264–3270.
   PubMed Web of Science ®Google Scholar
• Hogarty MD, Norris MD, Davis K, et al. ODC1 is a critical determinant of MYCN oncogenesis and a therapeutic target in neuroblastoma. Cancer Res. 2008;68:9735–9745.
   PubMed Web of Science ®Google Scholar
• Geerts D, Koster J, Albert D, et al. The polyamine metabolism genes ornithine decarboxylase and antizyme 2 predict aggressive behavior in neuroblastomas with and without MYCN amplification. Int J Cancer. 2010;126:2012–2024.
   PubMed Web of Science ®Google Scholar
• Sholler G, Ferguson W, Bergendahl G, et al. A phase II prevention trial of DFMO in patients with high risk neuroblastoma in remission prevents relapse and increases event free and overall survival. Presented at the American Society of Pediatric Hematology/Oncology annual meeting. Minneapolis. 2016 May.
   Google Scholar
• Sholler G, Ferguson W, Bergandahl G, et al. DFMO maintains remission and increases overall survival in high-risk neuroblastoma: results of a phase ii prevention trial. Presented at the Advances in Neuroblastoma Research Conference, Cairns, Australia, 2016 June.
   Google Scholar
• London WB, Castel V, Monclair T, et al. Clinical and biologic features predictive of survival after relapse of neuroblastoma: a report from the International Neuroblastoma Risk Group project. J Clin Oncol. 2011;29:3286–3292.
   PubMed Web of Science ®Google Scholar
• Lau L, Tai DWeitzman S, et al. Factors influencing survival in children with recurrent neuroblastoma. J Pediatr Hematol Oncol. 2004;26:227–232.
   PubMed Web of Science ®Google Scholar
• Garaventa A, Parodi S, De Bernardi B, et al. Outcome of children with neuroblastoma after progression or relapse. A retrospective study of the Italian neuroblastoma registry. Eur J Cancer. 2009;45:2835–2842.
   PubMed Web of Science ®Google Scholar
• Moreno L, Rubie H, Varo A, et al.Outcome of children with relapsed or refractory neuroblastoma: A meta-analysis of ITCC/SIOPEN European phase II clinical trials. Pediatr Blood Cancer. 2017; 64:25–31.
   Web of Science ®Google Scholar
• Modak S Generation and administration of autologous T cells transduced with a 3rd generation GD2 chimeric antigen receptor for patients with relapsed or refractory neuroblastoma. Presented at the Advances in Neuroblastoma Research Conference, Cologne, Germany,2014 June.
   Google Scholar
• Houghton PJ, Cheshire PJ, Hallman JD, et al. Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother Pharmacol. 1995;36:393–403.
   PubMed Web of Science ®Google Scholar
• Carol H, Houghton PJ, Morton CL, et al. Initial testing of topotecan by the pediatric preclinical testing program. Pediatr Blood Cancer. 2010;54(7): 07–715.
   Web of Science ®Google Scholar
• Blaney S, Berg SL, Pratt C, et al. A phase I study of irinotecan in pediatric patients: a Pediatric Oncology Group study. Clin Cancer Res. 2001;7:32–37.
   PubMed Web of Science ®Google Scholar
• Blaney SM, Needle MN, Gillespie A, et al. Phase II trial of topotecan administered as 72-hour continuous infusion in children with refractory solid tumors: a Collaborative Pediatric Branch, National Cancer Institute, and Children’s Cancer Group study. Clin Cancer Res. 1998;4:357–360.
   PubMed Web of Science ®Google Scholar
• Hawkins DS, Bradfield S, Whitlock JA, et al. Topotecan by 21-day continuous infusion in children with relapsed or refractory solid tumors: a Children’s Oncology Group study. Pediatr Blood Cancer. 2006;47:790–794.
   PubMed Web of Science ®Google Scholar
• Bomgaars LR, Bernstein M, Krailo M, et al. Phase II trial of irinotecan in children with refractory solid tumors: a Children’s Oncology Group study. J Clin Oncol. 2007;25:4622–4627.
   PubMed Web of Science ®Google Scholar
• Saylors RL, Stine KC, Sullivan J, et al. Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study. J Clin Oncol. 2001;19:3463–3469.
   PubMed Web of Science ®Google Scholar
• London WB, Frantz CN, Campbell LA, et al. Phase II randomized comparison of topotecan plus cyclophosphamide versus topotecan alone in children with recurrent or refractory neuroblastoma: a Children’s Oncology Group study. J Clin Oncol. 2010;28:3808–3815.
   PubMed Web of Science ®Google Scholar
• Kushner BH, Kramer K, Modak S, et al. Differential impact of high-dose cyclophosphamide, topotecan, and vincristine in clinical subsets of patients with chemoresistant neuroblastoma. Cancer. 2010;116:3054–3060.
   PubMed Web of Science ®Google Scholar
• Garaventa A, Luksch R, Biasotti S, et al. A phase II study of topotecan with vincristine and doxorubicin in children with recurrent/refractory neuroblastoma. Cancer. 2003;98:2488–2494.
   PubMed Web of Science ®Google Scholar
• Kushner BH, Kramer K, Modak S, et al. Irinotecan plus temozolomide for relapsed or refractory neuroblastoma. J Clin Oncol. 2006;24:5271–5276.
   PubMed Web of Science ®Google Scholar
• Bagatell R, London WB, Wagner LM, et al. Phase II study of irinotecan and temozolomide in children with relapsed or refractory neuroblastoma: a Children’s Oncology Group study. J Clin Oncol. 2011;29:208–213.
   PubMed Web of Science ®Google Scholar
• Kushner BH, Modak S, Kramer K, et al. Ifosfamide, carboplatin, and etoposide for neuroblastoma: a high-dose salvage regimen and review of the literature. Cancer. 2013;119:665–667.
   PubMed Web of Science ®Google Scholar
• Adbel Rahman H, Moussa EAH, Zekri WZK, et al. Did Salvage ICE chemotherapy improve the outcome in primary resistant/relapsing stage III/IV neuroblastoma? J Egypt Nat Cancer Inst. 2011;23:47–53.
   PubMedGoogle Scholar
• Donfrancesco A, Jenkner A, Castellano A, et al. Ifosfamide/carboplatin/etoposide (ICE) as front-line, topotecan/cyclophosphamide as second-line and oral temozolomide as third-line treatment for advanced neuroblastoma over one year of age. Acta Pediatr Suppl. 2004;445:6–11.
   Google Scholar
• Hutchinson RJ, Sisson JC, Shapiro B, et al. 131-I-metaiodobenzylguanidine treatment in patients with refractory advanced neuroblastoma. Am J Clin Oncol. 1992;15:226–232.
   PubMed Web of Science ®Google Scholar
• Klingebiel T, Berthold F, Treuner J, et al. Metaiodobenzylguanidine (MIBG) in treatment of 47 patients with neuroblastoma: results of the German neuroblastoma trial. Med Pediatr Oncol. 1991;19:84–88.
   PubMedGoogle Scholar
• Lashford LS, Lewis IJ, Fielding SL, et al. Phase I/II study of iodine 131 metaiodobenzylguanidine in chemoresistant neuroblastoma: a United Kingdom Children’s Cancer Study Group investigation. J Clin Oncol. 1992;10:1889–1896.
   PubMed Web of Science ®Google Scholar
• Matthay KK, Yanik G, Messina J, et al. Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma. J Clin Oncol. 2007;25:1054–1060.
   PubMed Web of Science ®Google Scholar
• Caren H, Abel F, Kogner P, et al. High incidence of DNA mutations and gene amplifications of the ALK gene in advanced sporadic neuroblastoma tumors. Biochem J. 2008;416:153–159.
   PubMed Web of Science ®Google Scholar
• Passoni L, Longo L, Collini P, et al. Mutation-independent anaplastic lymphoma kinase overexpression in poor prognosis neuroblastoma patients. Cancer Res. 2009;69:7338–7346.
   PubMed Web of Science ®Google Scholar
• Mosse YP, Lim MS, Voss SD, et al. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children’s Oncology Group phase 1 consortium study. Lancet Oncol. 2013;14:472–480.
   PubMed Web of Science ®Google Scholar
• Moore NF, Azarova AM, Bhatnagar N, et al. Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in ALK-mutated neuroblastoma. Oncotarget. 2014;5:8737–8749.
   PubMed Web of Science ®Google Scholar
• Sasaki T, Okuda K, Zheng W, et al. The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers. Cancer Res. 2010;70:10038–10043.
   PubMed Web of Science ®Google Scholar
• Berry T, Luther W, Bhatnagar N, et al. The ALK(F1174L) mutation potentiates the oncogenic activity of MYCN in neuroblastoma. Cancer Cell. 2012;22:117–130.
   PubMed Web of Science ®Google Scholar
• Zhou H, Kuang J, Zhong L, et al. Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy, and transformation. Nat Genet. 1998;20:189–193.
   PubMed Web of Science ®Google Scholar
• Sen S, Katayama H, Sasai K. Functional significance of aurora kinase A in centrosome amplification and genomic instability. Adv Exp Med Biol. 2008;617:99–108.
   PubMed Web of Science ®Google Scholar
• Shang X, Burlingame SM, Okcu MF, et al. Aurora A is a negative prognostic factor and a new therapeutic target in human neuroblastoma. Mol Cancer Ther. 2009;8:2461–2469.
   PubMed Web of Science ®Google Scholar
• Otto T, Horn S, Brockmann M, et al. Stabilization of N-Myc is a critical function of Aurora A in human neuroblastoma. Cancer Cell. 2009;15:67–78.
   PubMed Web of Science ®Google Scholar
• Mosse´ YP, Lipsitz E, Fox E, et al. Pediatric phase I trial and pharmacokinetic study of MLN8237, an investigational oral selective small-molecule inhibitor of Aurora kinase A: a Children’s Oncology Group phase I consortium study. Clin Cancer Res. 2012;18:6058–6064.
   PubMed Web of Science ®Google Scholar
• Dubois SG, Marachelian A, Fox E, et al. Phase I study of the aurora A kinase inhibitor alisertib in combination with irinotecan and temozolomide for patients with relapsed or refractory neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial. J Clin Oncol. 2016;34:1368–1375.
   PubMed Web of Science ®Google Scholar
• Saulnier Sholler GL, Gerner EW, Bergendahl G, et al. A phase I trial of DFMO targeting polyamine addiction in patients with relapsed/refractory neuroblastoma. Plos ONE. 2015;10:e0127246.
   PubMed Web of Science ®Google Scholar
• Peirce SK, Findley HW, Prince C, et al. The PI-3 kinase-Akt-MDM2-survivin signaling axis in high-risk neuroblastoma: a target for PI-3 kinase inhibitor intervention. Cancer Chemother Pharmacol. 2011;68:325–335.
   PubMed Web of Science ®Google Scholar
• Bern C. Antitrypanosomal therapy for chronic Chagas’ disease. New Engl J Med. 2011;364:2527–2534.
   PubMed Web of Science ®Google Scholar
• Rassi A, Rassi A, Marin-Neto JA. Chagas disease. Lancet. 2010;375:1388–1402.
   PubMed Web of Science ®Google Scholar
• Saulnier Sholler G, Brard L, Straub JA, et al. Nifurtimox induces apoptosis of neuroblastoma cells in vitro and in vivo. J Pediatr Hematol Oncol. 2009;31:187–193.
   PubMed Web of Science ®Google Scholar
• Du M, Zhang L, Scorsone KA, et al. Nifurtimox is effective against neural tumor cells and is synergistic with buthionine sulfoximine. Sci Rep. 2016;6:27458.
   PubMed Web of Science ®Google Scholar
• Saulnier Sholler GL, Bergendahl GM, Brard L, et al. A phase 1 study of nifurtimox in patients with relapsed/refractory neuroblastoma. J Pediatr Hematol Oncol. 2011;33:25–30.
   PubMed Web of Science ®Google Scholar
• Saulnier Sholler GL, Ferguson W, Bergendahl G, et al. A pilot trial testing the feasibility of using molecular-guided therapy in patients with recurrent neuroblastoma. J Cancer Ther. 2012;3:602–612.
   Google Scholar
• Saulnier Sholler GL, Bond JP, Bergendahl G, et al. Feasibility of implementing molecular-guided therapy for the treatment of patients with relapsed or refractory neuroblastoma. Cancer Med. 2015;4:871–886.
   PubMed Web of Science ®Google Scholar
• Mody RJ, Wu Y-M, Lonigro RJ, et al. Integrative clinical sequencing in the management of refractory or relapsed cancer in youth. JAMA. 2015;314:913–925.
   PubMed Web of Science ®Google Scholar
• Cha A, Asgharzedeh S, Czarnecki S, et al. Dinutuximab combined with chemotherapy in patients with multiply relapsed/refractory high risk neuroblastoma (HR-NBL). Presented at the Advances in Neuroblastoma Research Conference, Cairns, Australia, 2016 June.
   Google Scholar
• Shusterman S, London WB, Gillies SD, et al. Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children’s Oncology Group (COG) phase II study. J Clin Oncol. 2010;28:4969–4975.
   PubMed Web of Science ®Google Scholar
• Delgado DC, Hank JA, Kolesar J, et al. Genotypes of NK cell KIR receptors, their ligands, and Fcγ receptors in the response of neuroblastoma patients to Hu14.18-IL2 immunotherapy. Cancer Res. 2010;70:9554–9561.
   PubMed Web of Science ®Google Scholar
• Cheung NK, Sowers R, Vickers AJ, et al. FCGR2A polymorphism is correlated with clinical outcome after immunotherapy of neuroblastoma with anti-GD2 antibody and granulocyte macrophage colony stimulating factor. J Clin Oncol. 2006;24:2885–2890.
   PubMed Web of Science ®Google Scholar
• Merchant MS, Baird K, Wexler LH, et al. Ipilimumab: first results of a phase I trial in pediatric patients with advanced solid tumors. J Clin Oncol. 2012;30:9545.
   Web of Science ®Google Scholar
• Russell HV, Strother D, Mei Z, et al. Phase I trial of vaccination with autologous neuroblastoma tumor cells genetically modified to secrete IL-2 and lymphotactin. J Immunother. 2007;30:227–233.
   PubMed Web of Science ®Google Scholar
• Krishnadas DK, Shapiro T, Lucas K. Complete remission following decitabine/dendritic cell vaccine for relapsed neuroblastoma. Pediatrics. 2013;131:e336–e341.
   PubMed Web of Science ®Google Scholar
• Kanold J, Paillard C, Tchirkov A, et al. NK Cell immunotherapy for high-risk neuroblastoma relapse after haploidentical HSCT. Pediatr Blood Cancer. 2012;59:739–742.
   PubMed Web of Science ®Google Scholar
• Lee DW, Barrett DM, Mackall C, et al. The future is now: chimeric antigen receptors as new targeted therapies for childhood cancer. Clin Cancer Res. 2012;18:2780–2790.
   PubMed Web of Science ®Google Scholar
• Louis CU, Savoldo B, Dotti G, et al. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood. 2011;118:6050–6056.
   PubMed Web of Science ®Google Scholar
• Pule MA, Savoldo B, Myers GD, et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med. 2008;14:1264–1270.
   PubMed Web of Science ®Google Scholar
• Jena B, Dotti G, Cooper LJN. Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor. Blood. 2010;116:1035–1044.
   PubMed Web of Science ®Google Scholar
• Pession A, Tonelli R. The MYCN oncogene as a specific and selective drug target for peripheral and central nervous system tumors. Curr Cancer Drug Targets. 2005;5:273–283.
   PubMed Web of Science ®Google Scholar
• Puissant A, Frumm SM, Alexe G, et al. Targeting MYCN in neuroblastoma by BET bromodomain inhibition. Cancer Discov. 2013;3:308–323.
   PubMed Web of Science ®Google Scholar
• Shukla N, Ameur N, Yilman I, et al. Oncogene mutation profiling of pediatric solid tumors reveals significant subsets of embryonal rhabdomyosarcoma and neuroblastoma with mutated genes in growth signaling pathways. Clin Cancer Res. 2011;18:748–757.
   PubMed Web of Science ®Google Scholar
• Eleveld TF, Oldridge DA, Bernard V, et al. Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations. Nat Gen. 2015;47:864–871.
   PubMed Web of Science ®Google Scholar
• Holzel M, Huang S, Koster J, et al. NF1 is a tumor suppressor in neuroblastoma that determines retinoic acid response and disease outcome. Cell. 2010;142:218–229.
   PubMed Web of Science ®Google Scholar
• Woodfield SE, Zhang L, Scorsone K, et al. Binimetinib Inhibits MEK and is effective against neuroblastoma tumor cells with low NF1 expression. BMC Cancer. 2016;16:172.
   PubMed Web of Science ®Google Scholar
• Oppenheimer O, Cheung N-K, Gerald WL. The RET oncogene is a critical component of transcriptional programs associated with retinoic acid-induced differentiation in neuroblastoma. Mol Cancer Ther. 2007;6:1300–1309.
   PubMed Web of Science ®Google Scholar
• Zage PE, Zeng L, Palla S, et al. A novel therapeutic combination for neuroblastoma: the VEGFR/EGFR/RET inhibitor vandetanib with 13-cis-retinoic acid. Cancer. 2010;116:2465–2475.
   PubMed Web of Science ®Google Scholar
• Grinshtein N, Datti A, Fujitani N, et al. Small molecule kinase inhibitor screen identifies polo-like kinase 1 as a target for neuroblastoma tumor-initiating cells. Cancer Res. 2011;71:1385–1395.
   PubMed Web of Science ®Google Scholar
• Cole KA, Huggins J, Laquaglia M, et al. RNAi screen of the protein kinome identifies checkpoint kinase 1 (CHK1) as a therapeutic target in neuroblastoma. Proc Natl Acad Sci USA. 2011;108:3336–3341.
   PubMed Web of Science ®Google Scholar
• Balamuth NJ, Wood A, Wang Q, et al. Serial transcriptome analysis and cross-species integration identifies centromere-associated protein E as a novel neuroblastoma target. Cancer Res. 2010;70:2749–2758.
   PubMed Web of Science ®Google Scholar
• Cohen LE, Gordon JH, Popovsky EY, et al. Late effects in children treated with intensive multimodal therapy for high-risk neuroblastoma: high incidence of endocrine and growth problems. Bone Marrow Transplant. 2014;49:502–508.
   PubMed Web of Science ®Google Scholar
• Moreno L, Vaidya SJ, Pinkerton CR, et al. Long-term follow-up of children with high-risk neuroblastoma: the ENSG5 trial experience. Pediatr Blood Cancer. 2013;60:1135–1140.
   PubMed Web of Science ®Google Scholar
• Laverdiere C, Cheung NK, Kushner BH, et al. Long-term complications in survivors of advanced stage neuroblastoma. Pediatr Blood Cancer. 2005;45:324–332.
   PubMed Web of Science ®Google Scholar
• Trahair TN, Vowels MR, Johnston K, et al. Long-term outcomes in children with high-risk neuroblastoma treated with autologous stem cell transplantation. Bone Marrow Transplant. 2007;40:741–746.
   PubMed Web of Science ®Google Scholar
• Laverdière C, Liu Q, Yasui Y, et al. Long-term outcomes in survivors of neuroblastoma: a report from the Childhood Cancer Survivor Study. J Natl Cancer Inst. 2009;101:1131–1140.
   PubMed Web of Science ®Google Scholar
• Hobbie WL, Moshang T, Carlson CA, et al. Late effects in survivors of tandem peripheral blood stem cell transplant for high-risk neuroblastoma. Pediatr Blood Cancer. 2008;51:679–683.
   PubMed Web of Science ®Google Scholar
• Fawzy M, El-Beltagy M, Shafei ME, et al. Intraspinal neuroblastoma: treatment options and neurological outcome of spinal cord compression. Oncol Lett. 2015;9:907–911.
   PubMed Web of Science ®Google Scholar
• Applebaum MA, Henderson TO, Lee SM, et al. Second malignancies in patients with neuroblastoma: the effects of risk-based therapy. Pediatr Blood Cancer. 2015;62:128–133.
   PubMed Web of Science ®Google Scholar
• Federico SM, Allewelt HB, Spunt SL, et al. Subsequent malignant neoplasms in pediatric patients initially diagnosed with neuroblastoma. J Pediatr Hematol Oncol. 2015;37:e6–e12.
   PubMed Web of Science ®Google Scholar
• Martin A, Schneiderman J, Helenowski IB, et al. Secondary malignant neoplasms after high-dose chemotherapy and autologous stem cell rescue for high-risk neuroblastoma. Pediatr Blood Cancer. 2014;61:1350–1356.
   PubMed Web of Science ®Google Scholar
• Polishchuk AL, DuBois SG, Haas-Kogan D, et al. Response, survival, and toxicity after iodine-131-metaiodobenzylguanidine therapy for neuroblastoma in preadolescents, adolescents, and adults. Cancer. 2011;117:4286–4293.
   PubMed Web of Science ®Google Scholar
• Quach A, Ji L, Mishra V, et al. Thyroid and hepatic function after high-dose 131I metaiodobenzylguanidine (131I-MIBG) therapy for neuroblastoma. Pediatr Blood Cancer. 2011;56:191–201.
   PubMed Web of Science ®Google Scholar